BioAtla (BCAB) EBIT (2020 - 2026)

BioAtla (BCAB) has reported EBIT for 7 consecutive years, with $227000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBIT rose 101.22% year-over-year to $227000.0; the trailing twelve-month figure through Jun 2026 stood at -$32.1 million (up 49.63% YoY), and the FY2025 full-year result was -$59.3 million, up 19.8% from the prior year.
• EBIT grew to $227000.0 in Q2 2026 per BCAB's latest filing, from -$9.3 million in the prior quarter.
• Across five years, EBIT topped out at $227000.0 in Q2 2026 and bottomed at -$37.2 million in Q2 2023.
• Historically, EBIT has averaged -$21.1 million across 5 years, with a median of -$23.2 million in 2022.
• The sharpest annual moves came in 2023 and 2026: EBIT slumped 33.77% in 2023, then soared 101.22% in 2026.
• Over 5 years, EBIT stood at -$28.6 million in 2022, then gained by 0.08% to -$28.5 million in 2023, then jumped by 43.08% to -$16.2 million in 2024, then soared by 43.03% to -$9.3 million in 2025, then surged by 102.45% to $227000.0 in 2026.
• According to Business Quant data, EBIT over the past three periods registered $227000.0, -$9.3 million, and -$9.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.